CARDIO-TTRansform trial investigating eplontersen fails to meet primary efficacy endpoint
The CARDIO-TTRansform clinical trial, which was investigating the drug eplontersen for patients with transthyretin-mediated amyloid cardiomyopathy, did not achieve its primary efficacy endpoint. These results were presented at the ESC Congress 2026.
Why it matters
This news is significant for pharmaceutical companies, medical researchers, and patients suffering from transthyretin-mediated amyloid cardiomyopathy, as it indicates a setback in the development of a potential new treatment for this condition.
Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health A-Z Drugs Medical Devices Interviews White Papers More... MediKnowledge eBooks Posters Podcasts Videos Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Top Health Categories Coronavirus Disease COVID-19 Diet & Nutrition Artificial Intelligence Allergies Alzheimer's & Dementia Arthritis & Rheumatology Breast Cancer Breastfeeding Cold, Flu & Cough Dermatology Diabetes Eating Disorders Eye Health Gastrointestinal Health Heart Disease Lung Cancer Mental Health Parkinson's Disease Pregnancy Sleep Urology View Health A-Z Top Health Categories Coronavirus Disease COVID-19 Eating Disorders Diet & Nutrition Eye Health Artificial Intelligence Gastrointestinal Health Allergies Heart Disease Alzheimer's & Dementia Lung Cancer Arthritis & Rheumatology Mental Health Breast Cancer Parkinson's Disease Breastfeeding Pregnancy Cold, Flu & Cough Sleep Dermatology Urology Diabetes View Health A-Z Medical Home Life Sciences Home About News Life Sciences…
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in